Premium
A population‐based study of concurrent prescriptions of opioid analgesic and selective serotonin reuptake inhibitor medications during pregnancy and risk for adverse birth outcomes
Author(s) -
Sujan Ayesha C.,
Rickert Martin E.,
Quinn Patrick D.,
Ludema Christina,
Wiggs Kelsey K.,
Larsson Henrik,
Lichtenstein Paul,
Almqvist Catarina,
Öberg Anna Sara,
D'Onofrio Brian M.
Publication year - 2021
Publication title -
paediatric and perinatal epidemiology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.667
H-Index - 88
eISSN - 1365-3016
pISSN - 0269-5022
DOI - 10.1111/ppe.12721
Subject(s) - medicine , relative risk , pregnancy , medical prescription , confounding , population , obstetrics , absolute risk reduction , confidence interval , adverse effect , serotonin reuptake inhibitor , pediatrics , anxiety , psychiatry , antidepressant , pharmacology , genetics , environmental health , biology
Abstract Background Pregnant women with painful conditions often have mental health problems, including depression and anxiety. Co‐morbid conditions may cause pregnant women to use multiple medications, although safety of such practice is poorly understood. Objectives We investigated the influence of combined prescriptions of opioid analgesics and selective serotonin reuptake inhibitors (SSRIs) during pregnancy on two adverse birth outcomes. Methods We analysed Swedish population‐based births (n = 688 914) between 2007 and 2013. Using national registers, we obtained data on filled medication prescriptions, birth outcomes, and a wide range of parental characteristics. We estimated preterm birth and small‐for‐gestational‐age risk following independent or combined prescriptions of the two medications compared with no filled prescriptions for either medication. We adjusted for confounders using inverse probability of treatment weights. Results After adjusting for confounders, preterm birth risk was higher among women with opioid analgesic prescriptions only (5.9%; risk ratio [RR] 1.27, 95% confidence interval [CI] 1.22, 1.33), SSRIs only (6.2%; RR 1.34, 95% CI 1.27, 1.42), and both medications (7.8%; RR 1.70, 95% CI 1.47, 1.96) compared with unexposed women (4.6%). The interaction between the medications on preterm birth was small (risk difference [RD] 0.4%, 95% CI −0.8%, 1.6%); relative excess risk due to interaction [RERI] 0.09, 95% CI −0.17, 0.34; RR 1.00, 95% CI 0.85, 1.17). For small for gestational age, risk was approximately 2% across all groups, and there was no interaction between the medications (RD 0.3%, 95% CI −0.4%, 1.1%); RERI 0.15, 95% CI −0.16, 0.47; RR 1.15, 95% CI 0.87, 1.52). Conclusions Compared with unexposed pregnancies, those with either medication alone had a small increased risk for preterm birth but no increased risk for small for gestational age. The magnitude of associations with combined exposure to both medications were not greater than the sum of the associations with each medication considered individually.